Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Effects of other drugs on Tirabrutinib
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of other drugs on Tirabrutinib

1 evidence topic · 1 source

CYP3A4 and P-glycoprotein interactions

“Co-administration of the strong CYP3A4/P-gp inducer, rifampin, resulted in a significant decrease in tirabrutinib exposure (~70%).” (opens the source at this quote in a new tab)
“Co-administration of CYP3A4 inhibitors may increase tirabrutinib exposure.” (opens the source at this quote in a new tab)